Boryung’s new antihypertensive drug published in peer journal

Published: 2012-03-30 06:59:00

Updated: 2012-03-30 06:59:00

Boryung Pharmaceutical Co. says that the efficacy and safety of its Kanarb (fimasartan), a homegrown antihypertensive drug, are fully demonstrated in the global scientific arena.

The results of Phase III study of Kanarb, published in the latest issue of the international scientific journal Cli...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK